XML 37 R22.htm IDEA: XBRL DOCUMENT
v3.26.1

Share-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2025
Retirement Benefits [Abstract] |
Share-Based Compensation | 12. Share-Based Compensation Summary of Restricted Common Stock The following table summarizes restricted stock activity during the year ended December 31, 2025: Schedule of Restricted Stock
|  | Unvested Shares |  |  | Issuable Shares |  |  | Fair Value at Date of Issuance |  |  | Weighted Average Grant Date Fair Value |
Balance, December 31, 2024 |  |  | 1,320,834 |  |  |  | - |  |  | $ | 4,531,224 |  |  |  | 3.43 |
Granted |  |  | 450,000 |  |  |  | - |  |  |  | 405,000 |  |  |  | 0.90 |
Vested |  |  | (797,917 | ) |  |  | 797,917 |  |  |  | - |  |  |  | - |
Forfeited |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Issued |  |  | - |  |  |  | (797,917 | ) |  |  | (2,055,335 | ) |  |  | - |
Balance, December 31, 2025 |  |  | 972,917 |  |  |  | - |  |  | $ | 2,880,889 |  |  | $ | 2.96 |
On March 1, 2024, the Company granted its Chief Executive Officer 200,000 shares of the Company’s restricted stock and 225,000 shares of the Company’s restricted stock to other officers and employees with an aggregate fair value of $1,793,500 or $4.22 per share. The restricted stock grant vest 33% on the grant date, and 33% on each subsequent anniversary date. On February 1, 2025, the Company granted its Chief Executive Officer 250,000 shares of the Company’s restricted stock and granted 200,000 shares of the Company’s restricted stock to two other officers with an aggregate fair value of $405,000 or $0.90 per share. The restricted stock grant vests monthly over 36 months. During the years ended December 31, 2025 and 2024, the Company recognized stock-based compensation expense of $2,055,336 and $2,681,848, respectively, and issued 797,917 and 241,666 shares of restricted stock based on the vesting terms of the grants, respectively. As of December 31, 2025, the unamortized stock compensation expense for restricted stock amounted to $2,880,889, to be expensed upon vesting in future periods through February 2028. Summary of Stock Options The Company issues common stock and stock options as incentive compensation to directors and as compensation for the services of employees, contractors, and consultants of the Company. The fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The fair market value of the common stock is determined by reference to the quoted market price of the common stock on the grant date. The expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s common stock; the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award. A summary of stock option activity is presented below: Schedule of Stock Options
|  | Number of |  |  | Weighted Average |
|  | Options |  |  | Exercise Price |
Stock options outstanding at December 31, 2023 |  |  | 743,116 |  |  |  | 4.43 |
Granted |  |  | 3,405,500 |  |  |  | - |
Exercised |  |  | (2,843 | ) |  |  | - |
Expired or forfeited |  |  | (23,943 | ) |  |  | - |
Stock options outstanding at December 31, 2024 |  |  | 4,121,830 |  |  | $ | 4.28 |
Granted |  |  | 1,170,000 |  |  |  | 0.92 |
Exercised |  |  | - |  |  |  | 3.35 |
Expired or forfeited |  |  | (1,244,608 | ) |  |  | (1.05 | )
Stock options outstanding at December 31, 2025 |  |  | 4,047,222 |  |  | $ | 4.28 |
Stock options exercisable at December 31, 2025 |  |  | 2,519,444 |  |  | $ | 4.32 |
On April 1, 2024, the Company, pursuant to the terms of its 2019 Stock Incentive Plan, granted options exercisable into 3,405,500 shares of the Company’s common stock to be issued to its executives and employees. The 3,405,500 stock options had an exercise price of $4.01 per share, with 33% vesting on April 1, 2024, and 33% on each subsequent anniversary date. The stock options are exercisable at a weighted average price of $4.01 per share with an average life to expiration of approximately nine years. The total fair value of these options at the grant date was approximately $13,500,000, which was determined using a Black-Scholes option pricing model with the following average assumption: stock price of $4.01 per share, expected term of 6.00 years, volatility of 220%, dividend rate of 0%, and weighted average risk-free interest rate of 4.33%. On February 1, 2025, the Company, pursuant to the terms of its 2019 Stock Incentive Plan, granted options exercisable into 1,170,000 shares of the Company’s common stock to its executives and employees. The stock options vest equally over 36 months. The stock options are exercisable at a weighted average price of $0.92 per share with an average life to expiration of approximately three years. The total fair value of these options at grant date was approximately $1,073,000, which was determined using a Black-Scholes option pricing model with the following average assumption: stock price of $0.92 per share, expected term of 6.00 years, volatility of 241%, dividend rate of 0%, and weighted average risk-free interest rate of 4.45%. During the year ended December 31, 2025 and December 31, 2024, the Company recognized $3,671,565 and $8,031,290 of stock compensation expense relating to vested stock options, respectively. As of December 31, 2025, the aggregate amount of unvested compensation related to stock options was approximately $1,109,667 which will be recognized as an expense as the options vest in future periods through February 2028. The weighted average remaining contractual life of common stock options outstanding and exercisable at December 31, 2025 was 8.16 years. Based on a fair market value of $1.03 per share on December 31, 2025, the intrinsic value attributed to exercisable but unexercised common stock options was $178,975 at December 31, 2025. The exercise prices of common stock options outstanding and exercisable at December 31, 2025 are as follows: Schedule of Options Summarized by Exercise Price
Exercise Prices |  |  | Options Outstanding (Shares) |  |  | Options Exercisable (Shares) |
$ | 0.92 |  |  |  | 992,222 |  |  |  | 318,611 |
$ | 1.05 |  |  |  | 7,500 |  |  |  | 7,500 |
$ | 1.25 |  |  |  | 24,000 |  |  |  | 24,000 |
$ | 1.50 |  |  |  | 400,000 |  |  |  | 400,000 |
$ | 3.35 |  |  |  | 61,000 |  |  |  | 61,000 |
$ | 4.42 |  |  |  | 2,562,500 |  |  |  | 1,708,333 |
|  |  |  |  | 4,047,222 |  |  |  | 2,519,444 |

X
- Definition The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/712/tableOfContent Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/710/tableOfContent Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_CompensationAndEmployeeBenefitPlansTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CompensationAndRetirementDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration